Explore how industry leaders are adapting and evolving their strategies in this Trendline.
Large pharma faces growing challenges, from looming patent cliffs and heightened FTC scrutiny on M&A to regulatory shifts like Medicare price negotiations and new trade tariffs. In response, they are refining strategies by prioritizing lower-risk pipeline investments, optimizing R&D, and maximizing the value of existing drugs through new delivery methods and expanded indications.
INCLUDED IN THIS TRENDLINE
- With uncertainty roiling Big Pharma, execs are placing lower-risk bets
- Merck, Lilly launch manufacturing R&D consortium to help ‘bolster’ U.S. production
- Will 2025 mark pharma’s pivot to bigger deals after years of lackluster M&A?
Offered Free by: PharmaVoice and Thermo Fisher Scientific
See All Resources from: PharmaVoice and Thermo Fisher Scientific
